查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1620370

Atosiban的全球市场规模:各类型，各用途，各地区，范围及预测

Global Atosiban Market Size By Type (Injection, Concentrate), By Application (Hospitals, Online, Retail), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

Atosiban的市场规模与预测

2023 年Atosiban市场规模为 4.22 亿美元，预计在 2024-2030 年预测期内复合年增长率为 11.5%，到 2030 年达到 8.41 亿美元。由于孕妇早产、多胎妊娠、传染病以及糖尿病和高血压等慢性病的发生率不断上升，Atosiban市场正在扩大。Atosiban全球市场报告提供了对市场的整体评估。它对关键细分市场、趋势、市场推动因素、阻碍因素、竞争格局以及在市场中发挥关键作用的因素进行了全面分析。

全球Atosiban市场的定义

Atosiban是一种加压素和催产素受体拮抗剂，是一种合成的非胜肽脱氨催产素类似物。由于其能够透过抑制胞质内钙的释放和下调前列腺素的合成来减弱子宫收缩并增加子宫容受性，因此可用于预防或停止辅助生殖技术后的早产。

世界Atosiban市场概况

Atosiban是一种有效的子宫肌层收缩活化剂，对于足月和早产的开始都至关重要。早产率不断增加，刺激了Atosiban市场的扩张。由于孕妇多胎妊娠、传染病以及糖尿病和高血压等慢性病的增加，其盛行率正在增加。

世界卫生组织 (WHO) 估计，每年有 1,500 万婴儿早产，而且这个数字还在增加。在 184 个国家，5% 至 18% 的新生儿早产。健康怀孕在很大程度上可以减少死亡和与早产相关的问题。透过使用现代且具有成本效益的治疗方法，必须更频繁地避免这些悲剧。

个人化治疗的趋势正在影响Atosiban市场。遗传和药物基因组学研究正在帮助确定可以增强Atosiban治疗的患者特异性特征。此外，远距医疗和远距患者监测等数位健康工具可以改变Atosiban的管理和追踪方式，从而改善患者的治疗结果。

一些限制和困难可能会阻碍市场扩张。相关监管问题、医院基础设施缺乏以及农村地区孕产妇护理教育不足正在限制市场扩张。

目录

第1章 Atosiban的全球市场:简介

  • 市场定义
  • 市场区隔
  • 调查计划
  • 前提条件
  • 限制事项

第2章 VERIFIED MARKET RESEARCH的调查手法

  • 资料探勘
  • 资料的三角测量
  • Bottom-Up(由下而上)方法
  • Top-Down(由上而下)方法
  • 调查的流程
  • 产业专家的主要洞察
  • 资料来源

第3章 摘要整理

  • 市场概要
  • 生态学的製图
  • 绝对的商机
  • 市场魅力
  • Atosiban的全球市场各地区分析(年复合成长率)
  • Atosiban的全球市场:各类型(USD Million)
  • Atosiban的全球市场:各用途(USD Million)
  • 今后的市场机会
  • 全球市场明细
  • 产品life line

第4章 Atosiban的全球市场展望

  • 全球Atosiban的演进
  • 促进因素
  • 阻碍因素
  • 机会
  • 波特的五力分析
  • 价值链分析
  • 价格分析
  • 宏观经济分析

第5章 Atosiban的全球市场:各类型

  • 概要
  • 注射剂
  • 浓缩液

第6章 Atosiban的全球市场:各用途

  • 概要
  • 医院药局
  • 线上药局
  • 零售药局

第7章 Atosiban的全球市场:各地区

  • 概要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 南美
    • 巴西
    • 阿根廷
    • 其他南美国家
  • 中东·非洲
    • 阿拉伯联合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲

第8章 Atosiban的全球市场:竞争情形

  • 概要
  • 各公司的市场排行榜
  • 主要的发展
  • 企业的地区足迹
  • 企业的产业足迹
  • ACE矩阵

第9章 企业简介

  • Pfizer
  • Emcure Pharmaceuticals
  • Teva API
  • Ferring Pharmaceuticals
  • Sun Pharma
  • Shanghai Soho-Yiming Pharmaceuticals
  • EVER Pharma
  • Hangzhou Longshine Bio-Tech
  • Cayman Chemical
  • Neore Pharmaceutical
  • Hikma Pharmaceuticals
  • Lupin Pharmaceuticals
  • Bachem Group
  • Transo-Pharm Handels-GmbH
  • Rochem International Inc
  • Piramal Pharma Solutions

第10章 VERIFIED MARKET INTELLIGENCE

  • VERIFIED MARKET 关于INTELLIGENCE
  • 动态的资料的视觉化

第11章 附录

  • 相关调查
简介目录
Product Code: 11638

Atosiban Market Size And Forecast

Atosiban Market size was valued at USD 422 Million in 2023 and is projected to reach USD 841 Million by 2030 , growing at a CAGR of 11.5% during the forecast period 2024-2030. The market for Atosiban is expanding due to rising rates of preterm delivery, numerous pregnancies, infections, and chronic illnesses like diabetes and high blood pressure among pregnant women. The Global Atosiban Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors playing a substantial role in the market.

Global Atosiban Market Definition

A competitive vasopressin and oxytocin receptor antagonist, Atosiban is a synthetic nonpeptide desamino-oxytocin analog. Because of its capacity to lessen contractions and increase uterine receptivity by reducing intracytoplasmic calcium release and downregulating prostaglandin synthesis, it is used after assisted reproduction to prevent preterm birth and to stop premature labor.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Atosiban Market Overview

Atosiban is a potent activator of myometrial contractions and is crucial at the start of both term and preterm labor. Preterm birth rates are rising, fueling the market expansion for Atosiban. Prevalence is fueled by increased multiple pregnancies, infections, and chronic illnesses, including diabetes and high blood pressure among pregnant women.

The World Health Organization estimates that 15 million babies are born preterm each year, which is increasing. Between 5% and 18% of newborns are born preterm in 184 nations. A healthy pregnancy is heavily responsible for reducing preterm birth-related fatalities and problems. With the use of modern, cost-effective therapies, these tragedies must be avoided more frequently.

The trend toward personalized treatment is impacting the market for Atosiban. Genetic and pharmacogenomic investigations are aiding the identification of patient-specific characteristics that can enhance Atosiban treatment. Additionally, digital health tools like telemedicine and remote patient monitoring alter how Atosiban is administered and tracked, leading to better patient outcomes.

Some limitations and difficulties may prevent the market from expanding. Related regulatory issues, a lack of hospital infrastructure, and insufficient prenatal care education in rural areas constrain the market's expansion.

Global Atosiban Market Segmentation Analysis

The Global Atosiban Market is segmented on the basis of Type, Application, and Geography.

By Type

Injection

Concentrate

Based on the Type, The market is segmented into Injection and Concentrate. The Injection segment is anticipated to dominate the Global Atosiban market. The quick beginning of the effect of Atosiban injection is well established. It is helpful for instances where urgent tocolysis (inhibition of uterine contractions) is required since it can swiftly stop uterine contractions and delay preterm labor.

By Application

Hospitals

Online

Retail

Based on the Application, The market is segmented into Hospitals, Online, and Retail. The Hospitals segment is anticipated to dominate the Global Atosiban market. Most of the time, hospitals employ Atosiban, especially in labor and delivery or maternity wards. It is given intravenously by medical personnel to expectant mothers going through preterm labor.

By Geography

North America

Europe

Asia Pacific

Rest of the world

Based on the Regional Analysis, Global Atosiban is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America will hold the largest Global Atosiban market as preterm birth is still a significant healthcare concern. In recent years, preterm birth rates have increased in the area. This pattern has increased demand for medications such as Atosiban, which postpone preterm labor and lessen the risks of premature birth.

Key Players

The "Global Atosiban Market" study report will provide valuable insight emphasizing the global market. The major players in the market are

Pfizer, Emcure Pharmaceuticals, Teva API, Ferring Pharmaceuticals, Sun Pharma, Shanghai Soho-Yiming Pharmaceuticals, EVER Pharma, Hangzhou Longshine Bio-Tech, Cayman Chemical, Neore Pharmaceutical, Hikma Pharmaceuticals, Lupin Pharmaceuticals, Bachem Group, Transo-Pharm Handels-GmbH, Rochem International Inc, Piramal Pharma Solutions.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features and innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories

Active, Cutting Edge, Emerging, and Innovators.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Atosiban Market. We cover the major impacting factors driving the industry growth in the given region.

Porter's Five Forces

The image provided would further help to get information about Porter's five forces framework, providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the Global Atosiban Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ATOSIBAN MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Atosiban Market Geographical Analysis (CAGR %)
  • 3.6 Global Atosiban Market, By Type (USD Million)
  • 3.7 Global Atosiban Market, By Application (USD Million)
  • 3.8 Future Market Opportunities
  • 3.9 Global Market Split
  • 3.10 Product Life Line

4 GLOBAL ATOSIBAN MARKET OUTLOOK

  • 4.1 Global Atosiban Evolution
  • 4.2 Drivers
    • 4.2.1 Driver 1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint 1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity 1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL ATOSIBAN MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Injection
  • 5.3 Concentrate

6 GLOBAL ATOSIBAN MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Hospital Pharmacies
  • 6.3 Online Pharmacies
  • 6.4 Retail Pharmacies

7 GLOBAL ATOSIBAN MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Italy
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Argentina
    • 7.5.3 Rest of Latin America
  • 7.6 Middle-East and Africa
    • 7.6.1 UAE
    • 7.6.2 Saudi Arabia
    • 7.6.3 South Africa
    • 7.6.4 Rest of Middle-East and Africa

8 GLOBAL Atosiban MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Developments
  • 8.4 Company Regional Footprint
  • 8.5 Company Industry Footprint
  • 8.6 ACE Matrix

9 COMPANY PROFILES

  • 9.1 Pfizer
    • 9.1.1 Company Overview
    • 9.1.2 Company Insights
    • 9.1.3 Product Benchmarking
    • 9.1.4 Key Development
    • 9.1.5 Winning Imperatives
    • 9.1.6 Current Focus & Strategies
    • 9.1.7 Threat from Competition
    • 9.1.8 SWOT Analysis
  • 9.2 Emcure Pharmaceuticals
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Teva API
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Ferring Pharmaceuticals
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Sun Pharma
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Shanghai Soho-Yiming Pharmaceuticals
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 EVER Pharma
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Hangzhou Longshine Bio-Tech
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Cayman Chemical
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Neore Pharmaceutical
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments
  • 9.11 Hikma Pharmaceuticals
    • 9.11.1 Overview
    • 9.11.2 Financial Performance
    • 9.11.3 Product Outlook
    • 9.11.4 Key Developments
  • 9.12 Lupin Pharmaceuticals
    • 9.12.1 Overview
    • 9.12.2 Financial Performance
    • 9.12.3 Product Outlook
    • 9.12.4 Key Developments
  • 9.13 Bachem Group
    • 9.13.1 Overview
    • 9.13.2 Financial Performance
    • 9.13.3 Product Outlook
    • 9.13.4 Key Developments
  • 9.14 Transo-Pharm Handels-GmbH
    • 9.14.1 Overview
    • 9.14.2 Financial Performance
    • 9.14.3 Product Outlook
    • 9.14.4 Key Developments
  • 9.15 Rochem International Inc
    • 9.15.1 Overview
    • 9.15.2 Financial Performance
    • 9.15.3 Product Outlook
    • 9.15.4 Key Developments
  • 9.16 Piramal Pharma Solutions
    • 9.16.1 Overview
    • 9.16.2 Financial Performance
    • 9.16.3 Product Outlook
    • 9.16.4 Key Developments

10. VERIFIED MARKET INTELLIGENCE

  • 10.1 About Verified Market Intelligence
  • 10.2 Dynamic Data Visualization

11 Appendix

  • 11.1 Related Research